or Try an Advanced Search...

    Technical Analysis for ATHE - Alterity Therapeutics Limited

    Grade Last Price % Change Price Change
    D 1.87 -0.54% -0.01
    ATHE closed down 0.54 percent on Friday, May 31, 2024, on 7 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ATHE trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    BB Squeeze + Lower Band Touch Range Contraction 0.00%
    Below Lower BB Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Bollinger Band Squeeze Range Contraction -0.54%
    Older End-of-Day Signals for ATHE ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low 1 day ago
    Down 1% 1 day ago
    Down 3% 3 days ago
    Down 2 % 3 days ago
    Down 1% 3 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ATHE Chart by TradingView
    Basic chart:

    Profile

    Alterity Therapeutics Ltd formerly known as Prana Biotechnology Ltd is active in the healthcare domain. The company is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Neuroscience Alzheimer's Disease Gastrointestinal Parkinson's Disease Neurology Toxicology Treatment Of Parkinson's Disease Huntington's Disease Movement Disorders Pathology Anatomical Pathology Brain Cancer Neuropathology Toxicology Testing Treatment Of Alzheimer's

    Is ATHE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
    Apr 30 Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
    Apr 29 Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
    Apr 17 Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
    Apr 11 ATUS, ATHE and GRFS among pre-market losers
    Apr 10 Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
    Feb 23 Alterity Therapeutics drops on capital raise
    Feb 20 Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
    Jan 29 Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
    Jan 22 Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
    See more ATHE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.41
    52 Week Low 1.55
    Average Volume 90,942
    200-Day Moving Average 2.26
    50-Day Moving Average 2.05
    20-Day Moving Average 2.00
    10-Day Moving Average 1.95
    Average True Range 0.15
    RSI (14) 41.18
    ADX 19.15
    +DI 18.30
    -DI 18.25
    Chandelier Exit (Long, 3 ATRs) 1.84
    Chandelier Exit (Short, 3 ATRs) 2.29
    Upper Bollinger Bands 2.12
    Lower Bollinger Band 1.88
    Percent B (%b) -0.03
    BandWidth 12.07
    MACD Line -0.05
    MACD Signal Line -0.03
    MACD Histogram -0.0149
    Fundamentals Value
    Market Cap 13.66 Million
    Num Shares 7.3 Million
    EPS -1.86
    Price-to-Earnings (P/E) Ratio -1.01
    Price-to-Sales 3.73
    Price-to-Book 0.99
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.92
    Resistance 3 (R3) 1.91 1.90 1.91
    Resistance 2 (R2) 1.90 1.89 1.90 1.90
    Resistance 1 (R1) 1.88 1.88 1.89 1.89 1.90
    Pivot Point 1.87 1.87 1.87 1.87 1.87
    Support 1 (S1) 1.85 1.86 1.86 1.86 1.84
    Support 2 (S2) 1.84 1.85 1.84 1.84
    Support 3 (S3) 1.82 1.84 1.83
    Support 4 (S4) 1.83